| ESTECHPHARMA CO.,LTD., as one of the active pharmaceutical company,
is remarkably growing more than 30% every year by concentrating all
our efforts into developing new technologies by investing more than
15% of the annual turnover into R&D since our foundation in 1996.
That is company ideology, challenge and creation.
We've succeeded in synthesizing 40 kinds of APIs like Anti-inflammatory
medicine, Anti-ulcerants, Anti-hepatitis, Treatments of Alcoholism,
and etc secondly or thirdly in the world or firstly in Korea, and
have been producing and supplying continuously to our customers. In
present, with many patent technologies, we are co-operating new projects
with domestic and world pharmaceutical companies by developing new
materials new materials of Anti-hepatitis and Anti-inflammatory.
In sales part, all our officers and staffs are doing wholly our best
to enter the world pharmaceutical market based on domestic market's
experiment.
Especially, We are planning to start construction of a new plant
in this year(2006) which will be complied with the cGMP rules. New
construction of the cGMP plants means not only increasing of capacity
but also providing facilities which fit US FDA's and world's standard.
If cGMP qualified, it is estimated to accelerate our advancing in
the world pharmaceutical market and it makes us to be ready to enter
the world biggest market, USA. Considering only some companies are
qualified cGMP in domestic market, the constructions of cGMP plant
will benefit us to achieve our slogan "To be the leader of Active
Pharmaceutical Ingredient". We will do our best on construction
of the cGMP plant and will endeavor to be a global company with competitive
power in world API market. |
